Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Faeth Therapeutics, Inc. is a pioneering biotechnology company focused on transforming cancer treatment through its innovative approach to immunotherapy. Leveraging advanced protein engineering and proprietary technologies, Faeth aims to enhance the body's natural defenses to target and eliminate cancer cells effectively. The company's robust pipeline includes promising candidates that address significant unmet medical needs in oncology, positioning Faeth as a key player in the evolving landscape of cancer therapeutics. With a dedicated management team and strong scientific expertise, Faeth Therapeutics is poised to make substantial strides in improving patient outcomes in the fight against cancer.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$37.44
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 4, 2026 | $-1.10 | $-2.84 | Miss -158.2% | $-2.84 | $0 | $0 | — | 1D Pre+0.4% | On-Day-6.7% | 1D Post-3.6% |
Q ended Mar 31, 2026 Reported May 15, 2026 | $-0.62 | $-131.45 | Miss -21101.6% | $-131.45 | — | $0 | — | 1D Pre-6.0% | On-Day+3.1% | 1D Post-2.5% |
Q ended Dec 31, 2025 Reported Mar 30, 2026 | $-4.81 | $-3.74 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Beat +22.2% |
| — |
| — |
| $0 |
| — |
| 1D Pre+3.0% |
| On-Day-9.2% |
| 1D Post+25.4% |
Q ended Sep 30, 2025 Reported Nov 14, 2025 | $-4.11 | $-3.62 | Beat +11.9% | — | — | -$4.85M | — | 1D Pre-10.7% | On-Day-11.3% | 1D Post+1.7% |